Lipid nanoparticle mediated delivery of Anti-CD19 CAR mRNA to umbilical cord blood NK cells for targeting CD19⁺ primary B-ALL cells
- 17 December 2025
- journal article
- Published by Elsevier in Current Research in Translational Medicine
- Vol. 74 (1) , 103563
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Tehran University of Medical Sciences and Health Services (1402\u20134\u2013107\u201369972)
This publication has 83 references indexed in Scilit:
- Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potencyCancer Cell, 2025
- Evaluating the safety and feasibility of allogeneic NK cell infusion in high-risk lymphoma patients post-autologous stem cell transplantationDiscover Oncology, 2025
- Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell EngineeringAdvanced Healthcare Materials, 2023
- Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applicationsAdvanced Drug Delivery Reviews, 2023
- Advances in mRNA non-viral delivery approachesAdvanced Drug Delivery Reviews, 2021
- Side-effect management of chimeric antigen receptor (CAR) T-cell therapyAnnals of Oncology, 2021
- Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapyClinical and Translational Oncology, 2020
- Chimeric Antigen Receptor (CAR) T Cell Therapy for Cancer. Challenges and Opportunities: An Overview2020
- Endocytosis as a mechanism of regulating natural killer cell function: unique endocytic and trafficking pathway for CD94/NKG2AImmunologic Research, 2008
- Tricyclic Antidepressants Inhibit Human Natural Killer CellsToxicology and Applied Pharmacology, 1996